INHIBITION OF N-LINKED GLYCOSYLATION OF P-GLYCOPROTEIN BY TUNICAMYCIN RESULTS IN A REDUCED MULTIDRUG-RESISTANCE PHENOTYPE

被引:58
作者
KRAMER, R
WEBER, TK
ARCECI, R
RAMCHURREN, N
KASTRINAKIS, WV
STEELE, G
SUMMERHAYES, IC
机构
[1] NEW ENGLAND DEACONESS HOSP,DEPT SURG,CANC BIOL LAB,BOSTON,MA 02115
[2] AMER CYANAMID CO,DIV MED RES,PEARL RIVER,NY 10965
[3] DANA FARBER CANC INST,BOSTON,MA 02115
[4] CHILDRENS HOSP,BOSTON,MA 02115
关键词
P-GLYCOPROTEIN; GLYCOSYLATION; TUNICAMYCIN; MDR PHENOTYPE;
D O I
10.1038/bjc.1995.133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Characterisation of altered glycosylation of P-glycoprotein (P-gp) found associated with the absence of a multidrug resistance (MDR) phenotype in cell lines prompted an investigation to assess the role of post-translational processing in establishing P-gp efflux pump functionality. The clone A cell line used in this study displays a strong MDR phenotype mediated by high constitutive levels of expression of P-gp. Incubation of clone A cells with tunicamycin for different periods resulted in a time-dependent increase in daunorubicin accumulation, reflecting a reduction in P-gp function. Parallel experiments conducted with verapamil resulted in no loss of P-gp functionality in clone A cells. Reduction in surface-associated P-gp following exposure to tunicamycin was established by FAGS analysis, Western blot analysis and immunoprecipitation of surface-iodinated P-gp. In addition, immunoprecipitation of P-gp from P-32-orthophosphate-labelled cells demonstrated reduced phosphorylation of P-gp associated with tunicamycin exposure. From these studies we conclude that glycosylation of P-gp is required to establish the cellular MDR phenotype.
引用
收藏
页码:670 / 675
页数:6
相关论文
共 20 条
[1]  
AHMAD S, 1993, MOL PHARMACOL, V43, P858
[2]  
ARCECI RJ, 1993, CANCER RES, V53, P310
[3]   MODULATION OF P-GLYCOPROTEIN PHOSPHORYLATION AND DRUG TRANSPORT BY SODIUM-BUTYRATE [J].
BATES, SE ;
CURRIER, SJ ;
ALVAREZ, M ;
FOJO, AT .
BIOCHEMISTRY, 1992, 31 (28) :6366-6372
[4]  
BECK WT, 1982, CANCER RES, V42, P184
[5]  
CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679
[6]  
CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008
[7]   EFFECTS OF TUNICAMYCIN ON ANTHRACYCLINE RESISTANCE IN P388 MURINE LEUKEMIA-CELLS [J].
CHOU, TH ;
KESSEL, D .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (22) :3134-3136
[8]   ELECTROPHORETIC ANALYSIS OF P-GLYCOPROTEINS PRODUCED BY MOUSE J774.2 AND CHINESE-HAMSTER OVARY MULTIDRUG-RESISTANT CELLS [J].
GREENBERGER, LM ;
WILLIAMS, SS ;
GEORGES, E ;
LING, V ;
HORWITZ, SB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (07) :506-510
[9]  
HAMADA H, 1987, CANCER RES, V47, P2860
[10]   CONSTITUTIVE EXPRESSION OF MULTIDRUG-RESISTANCE IN HUMAN COLORECTAL TUMORS AND CELL-LINES [J].
KRAMER, R ;
WEBER, TK ;
MORSE, B ;
ARCECI, R ;
STANIUNAS, R ;
STEELE, G ;
SUMMERHAYES, IC .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :959-968